To assess the impact of the COVID-19 outbreak on the industry, BioCentury conducted a survey of biopharma executives and investors. Both groups expressed ample concern, but have taken little action to avoid business disruptions caused by the virus.
Now, BioCentury is making the analysis of the results available for download. The exclusive report provides critical insights on:
- The likelihood of clinical trial delays
- Concerns about companies’ abilities to meet clinical trials and other deadlines
- Disruptions to trial sites
- Shifts in program prioritization
- Fears surrounding the ability to raise money in the coming months
- And more...
You can’t find this level of analysis anywhere else.
Download the report now!